Predict your next investment

Corporation
aligo.ca

See what CB Insights has to offer

Investments

5

Portfolio Exits

1

About Aligo Innovation

Aligo Innovation is a university research commercialization company created in April of 2014 following the integration of Valeo and MSBiV's activities. The Company valorizes the research results of universities and their institutional partners from all areas of innovation, including life sciences, human health, animal health, pure and applied sciences, engineering, and information technology and communications.

Aligo Innovation Headquarter Location

355 Peel Suite 503

Montreal, Quebec, H3C 2G9,

Canada

514-840-1226

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aligo Innovation

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Aligo Innovation in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Aligo Innovation News

Laurent Pharmaceuticals Welcomes New Investors and Announces Scientific Breakthrough with LAU-7b in...

Oct 25, 2018

Share this article MONTREAL, Oct. 25, 2018 /PRNewswire/ - Laurent Pharmaceuticals Inc., a biopharmaceutical company developing LAU-7b (oral fenretinide) first-in-class pro-resolving drug for Cystic Fibrosis (CF), today announced new financing led by Keiretsu Forum Mid-Atlantic, Anges Quebec and Anges Quebec Capital, with participation from existing investors RSJ Gradus, Aligo Innovation, and Cystic Fibrosis Canada. Members from other Keiretsu Forum chapters also invested, as well as a select group of new and existing private individuals. "We are thrilled to see so many great investors embracing our mission", said Radu Pislariu, MD, President and CEO of Laurent Pharmaceuticals. "This new investment, together with the US$ 5M Development Award from US Cystic Fibrosis Foundation announced earlier this year, allows us to build on the progress made in developing LAU-7b, which we believe has the potential to make a life-changing impact for patients with CF". The Company also announces two posters featuring new important findings with fenretinide in CF, presented by McGill University at the 32nd North American Cystic Fibrosis Conference, held in Denver, October 18-20 (NACFC 2018). The data, reported by Drs Danuta Radzioch and John Hanrahan research groups, shows fenretinide's potential to modulate the CFTR functional response and mucin secretion under stress conditions, establishing an important link between inflammation and the basic defect in CF. Fenretinide's effect on CFTR expression was significantly enhanced in the presence of a CFTR corrector. "This is a major breakthrough discovery for our LAU-7b program in CF, said Dr Jean-Marie Houle, B.Pharm, PhD, the Company's Vice-President of Clinical Development. We knew fenretinide's ability to trigger the resolution mechanism of inflammation, which is profoundly downregulated in CF, but protecting the CFTR function adds a new dimension to LAU-7b, suggesting a double mode of action and a potentiating effect on CFTR modulators. We are extremely excited about this discovery by McGill, which is also timely as we are recruiting patients in the Phase 2 trial. Copies of both posters are accessible on the company's website at the following link: LAU-7b: a new treatment paradigm for cystic fibrosis LAU-7b is a first-in-class pro-resolving therapy that has the potential to treat chronic pulmonary inflammation that leads to irreversible lung damage in patients with CF, regardless of their CFTR genotype. As opposed to typical anti-inflammatory drugs that inhibit the activation phase of inflammation, LAU-7b triggers body's own pro-resolving mechanism to terminate inflammation without interfering with natural defense. More recently, LAU-7b was shown to enhance specific lipid micro-domains in the membrane of airways cells affected by CF, resulting in an increase in functional CFTR expression under cell stress, a self-protective mechanism that was further improved by co-administration of a CFTR corrector. Laurent Pharmaceuticals is currently recruiting patients for its Phase 2 safety and efficacy study in adult patients with CF. The goal of the Phase 2 trial is to evaluate LAU-7b's effect on the preservation of lung function, by reducing persistent unresolved inflammation in the lung and stimulating its return to homeostasis. The study will enroll 136 adults with CF for treatment duration of 6 months, and will involve more than 30 clinical sites in USA and Canada. About Cystic Fibrosis Cystic Fibrosis ("CF") is a progressive, life-threatening, genetic disease affecting about 75,000 people worldwide. CF is caused by various mutations in the CFTR gene and is characterized by viscous secretions in different exocrine tissues and an aberrant inflammatory response leading to chronic pulmonary infection and loss in lung function over time. Severe pulmonary dysfunction is the primary cause of death in CF. About LAU-7b LAU-7b (fenretinide) is a once-a-day oral pro-resolving therapy, a new class of drugs that triggers the resolution phase of inflammation, which is responsible for healing and return to homeostasis after a bacterial attack or injury. LAU-7b works by endogenously modulating the metabolism of docosahexaenoic acid (DHA), an essential fatty acid involved in the resolution of inflammation. Previous preclinical work at McGill University demonstrated the ability of fenretinide to restore DHA in a specific CF animal model of chronic inflammation, resulting in reduced lung inflammation, improved lung physiology and increased clearance of pulmonary infection with Pseudomonas aeruginosa, a bacterium involved in perpetuating the vicious cycle of inflammation-infection. Results from a recent Phase 1b clinical trial in adult patients with CF have shown LAU-7b to have good safety and pharmacokinetic profiles, coupled with promising pharmacodynamics on specific markers of inflammation. About Laurent Pharmaceuticals Laurent Pharmaceuticals is a Canada-based clinical stage company focusing on chronic inflammatory diseases. Laurent's lead drug candidate, LAU-7b, is a first-in-class pro-resolving drug addressing the compromised immune-inflammatory response in cystic fibrosis, a critical but still unaddressed pathogenic pathway leading to pulmonary insufficiency in patients with CF. For more information, please visit www.laurentpharma.com . SOURCE Laurent Pharmaceuticals

Aligo Innovation Investments

5 Investments

Aligo Innovation has made 5 investments. Their latest investment was in My Intelligent Machines as part of their Seed VC on September 9, 2019.

CBI Logo

Aligo Innovation Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/5/2019

Seed VC

My Intelligent Machines

$2.6M

Yes

5

10/25/2018

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

9/12/2017

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

6/9/2016

Seed

Subscribe to see more

$99M

Subscribe to see more

10

2/26/2016

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/5/2019

10/25/2018

9/12/2017

6/9/2016

2/26/2016

Round

Seed VC

Unattributed VC

Seed VC

Seed

Series A

Company

My Intelligent Machines

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$2.6M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

10

10

10

10

Aligo Innovation Portfolio Exits

1 Portfolio Exit

Aligo Innovation has 1 portfolio exit. Their latest portfolio exit was wrnch on September 17, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/17/2021

Acquired

1

Date

9/17/2021

Exit

Acquired

Companies

Valuation

Acquirer

Sources

1

Aligo Innovation Team

1 Team Member

Aligo Innovation has 1 team member, including former Senior Director, Frederic Lemaitre Auger.

Name

Work History

Title

Status

Frederic Lemaitre Auger

Senior Director

Former

Name

Frederic Lemaitre Auger

Work History

Title

Senior Director

Status

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.